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Abstract
We validate that the 28 days after hospital-discharge are high-risk for drugs-related death
(DRD) among drug users in Scotland and investigate key risk-factors for DRDs soon after
hospital-discharge. Using data from an anonymous linkage of hospitalisation and death rec-
ords to the Scottish Drugs Misuse Database (SDMD), including over 98,000 individuals reg-
istered for drug treatment during 1 April 1996 to 31 March 2010 with 705,538 person-years,
173,107 hospital-stays, and 2,523 DRDs. Time-at-risk of DRD was categorised as: during
hospitalization, within 28 days, 29–90 days, 91 days–1 year, >1 year since most recent hos-
pital discharge versus ‘never admitted’. Factors of interest were: having ever injected, mis-
use of alcohol, length of hospital-stay (0–1 versus 2+ days), and main discharge-diagnosis.
We confirm SDMD clients’ high DRD-rate soon after hospital-discharge in 2006–2010.
DRD-rate in the 28 days after hospital-discharge did not vary by length of hospital-stay but
was significantly higher for clients who had ever-injected versus otherwise. Three leading
discharge-diagnoses accounted for only 150/290 DRDs in the 28 days after hospital-dis-
charge, but ever-injectors for 222/290. Hospital-discharge remains a period of increased
DRD-vulnerability in 2006–2010, as in 1996–2006, especially for those with a history of
injecting.
Introduction
Injecting drug users experience significantly higher mortality rates [1–13], and identifying
opportunities of intervention, such as upon release from prison or expiry of methadone pre-
scription [5, 10], are important for public health policy.
Scotland has invested in record linkage for drug users to monitor blood born viruses and
prevalence of injecting drug users. Using record linkage, Merrall et al. [14] added to the litera-
ture of drug user mortality by showing that drug treatment clients were at increased risk of
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drugs-related death (DRD) within 28 days after hospital-discharge in Scotland in 1996–2006
(21 DRDs per 1,000 person-years (pys); 95% CI: 18, 25).
In this article, we first validate the findings by Merrall et al. [14] for 1996–2006 by investi-
gating SDMD clients’DRD-risk by time after hospital-discharge in 2006–2010. The injector
population is changing over time, as the progression and initiation of injectors changes through
social change and public health interventions, so it is important to validate past findings. Sec-
ondly, using the entire 1996–2010 SDMD cohort with the increased person-years of follow-
up–and hence increased statistical power- we are able to investigate more detailed hospital epi-
sode characteristics, such as duration of hospitalization and main discharge-diagnosis.
We confirm SDMD clients continue to experience higher drugs-related mortality rates after
hospital-discharge, and further that having been an injection drug user better identifies those
at highest DRD-risk soon after hospital-discharge than duration of hospital-stay or main dis-
charge-diagnosis.
Methods
The study of hard-to-reach populations, such as people who inject drugs, has been hugely facil-
itated by linkage between administrative records and confidential health registers, see for
example [3, 4, 6, 7, 9–13]. Scotland’s Information Services Division holds the Scottish Drugs
Misuse Database (SDMD), which records all registrations in Scotland for drug treatment or
support. By a variation on the Privacy Advisory Committee permissions for Scotland’s surveil-
lance of the late sequelae after hepatitis C virus diagnosis [15], we could access linked data for
the present study of SDMD clients’DRDs to 31 March 2010.
Study population and data sources
For each drug treatment registration in Scotland, the SDMD holds limited identifying informa-
tion: sex, date of birth, forename initial, first and fourth letter of the surname, and postcode
sector of residence. Data are also held on risk behaviors such as illicit drugs used, reported mis-
use of alcohol, and injecting drug user status at the time of SDMD registration. Linked SDMD
records were available on 98,388 individuals who attended drug treatment services between 1
April 1996 and 31 March 2010.
Deaths, hospital episodes and hepatitis C virus diagnoses of individuals registered on the
SDMD during April 1996 through March 2010 were identifiable through linkages with the
national registers held respectively by Information Services Division, National Records of Scot-
land (formerly the General Register Office for Scotland) and Health Protection Scotland. Rec-
ords were linked by Information Services Division using a probabilistic approach on the
available identifying information at the time of linkage. Note that these identifiers may have
changed between the linkages performed in 2006 and 2010. For each SDMD client, potentially
corresponding death, hospital records and hepatitis C virus records were ranked according to a
linkage score which was based on a probabilistically-weighted combination of the occurring
identifiers. The top-ranked match would be successful if the score exceeded a pre-determined
threshold (see Merrall [16] for further details).
The linked dataset was anonymized before transfer to Medical Research Council Biostatistics
Unit for analysis. This anonymization, together with updating of contributory records, explains
why linked-records for the same individual cannot assuredly be matched between successive link-
ages, such as for the 1996–2006 and updated 1996–2010 SDMD cohorts. Information Services
Division has previously estimated its procedure to have an error rate (either false positives or false
negatives) of less than 5% [17]. However, low-level inconsistencies inevitably remain. Moreover,
due to the updating of the contributory linkable records, the SDMD cohort for 1996–2006 is now
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reckoned as 74,654 registered clients (previously 69,457 [14]). There are thus actual differences in
the client, DRD, and person-year counts from those reported byMerrall et al. [14] for 1996–2006
but these differences have had no implications for the inferences drawn, which are robust.
Statistical analysis
We investigated DRDs as nationally defined by Jackson [18] and National Records of Scotland,
which comprise deaths involving drugs or attributed to one’s drug dependence and have the
following groupings: mental and behavioral disorders due to psychoactive substance misuse;
accidental poisoning; intentional self-poisoning by drugs, medicaments and biological sub-
stances; assault by drugs, medicaments and biological substances; and events of undetermined
intent, poisoning. See Table 1 for the specific International Classification of Disease codes (9th
& 10th version) corresponding to each grouping.
Each hospital record corresponds to an episode of care within a general/acute or mental
health specialty, respectively, in Scotland. The record is generated when a patient is discharged
Table 1. ICD codes for cause of death or hospital discharge.
Classification ICD 9 ICD 10
Infectious and parasitic diseases 001–139 A00–B99
Cancer 140–208 C00–C97
Endocrine, nutritional and metabolic diseases 240–279 E00–E89




Diseases of the nervous system 320–389 G00–G99
Diseases of the circulatory system 390–459 I00–I99
Diseases of the respiratory system 460–519 J00–J99














Accidental poisoning E850–E858 X40–X44
Intentional self-poisoning by drugs, medicaments
and biological substances
E950.0–E950.5 X60–X64
Assault by drugs, medicaments and biological
substances
E962.0 X85
Events of undetermined intent, poisoning E980.0–E980.5 Y10–Y14
Drugs-related morbidityb
Poisoning by drugs, medicaments and biological
substances
960–976 T36–T50
Mental and behavioural disorders due to
psychoactive substance misuse
292, 304 excluding 304.6 F11–F16, F19
Abreviations: DRD, drugs-related death; ICD, International Classification of Disease
a Any codes corresponding to drugs-related causes were excluded from other categories, so all are
mutually exclusive
b Category used only for hospital discharge diagnoses
doi:10.1371/journal.pone.0141073.t001
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or transferred between hospitals, specialties or consultants [19], and the duration of an episode
may range from a day-visit up to a stay of several months. Hence, a single hospital-stay may
comprise a series of episodes. Therefore, for each SDMD client, serial hospital episodes with
overlapping or matching end- and start-dates were coalesced as a single hospital-stay which
began at the set’s earliest start-date and ended on the latest end-date.
Duration of hospital-stay was computed as ‘latest end-date minus earliest start-date’, and is
thus measured in whole days with respect to the recorded admission and discharge dates. The
majority of hospital-stays were of one day or less, a large number were computed as zero-
length. Within the data it is not possible to derive an exact admission time, so we cannot distin-
guish between a short-stay that occurs over night and a stay for at least one day. Accordingly,
duration was summarized as 0–1 days versus 2+ days, the former accounting for brief episodes
that may or may not have included an over-night stay. The length of hospital-stay is highly
skewed, and exhibits a so-called zero-inflated distribution (meaning there are many individuals
with zero-length stays). With insufficient individuals to properly characterize longer stays, we
dichotomize into (conservatively defined) day visits (0-1days) or longer (2+ days).
Hospital episodes are recorded with a main discharge-diagnosis and supplementary dis-
charge diagnoses [4, 16]. We restrict attention to the main discharge-diagnosis of the last epi-
sode for each hospital-stay. The discharge codes for drug-related morbidity were classified
using the same groupings as for drug-related mortality but with the addition of poisoning by
drugs, medicaments and biological substances and mental and behavioral disorders due to psy-
choactive substance misuse. Further major categories of discharge-diagnosis were: infectious
and parasitic diseases; cancer; endocrine, nutritional and metabolic diseases; mental and behav-
ioral disorders—excluding those due to psychoactive substance misuse; diseases of the nervous
system; diseases of the circulatory system; diseases of the respiratory system; diseases of the
digestive system; and accidental. See Table 1 for the specific International Classification of Dis-
ease codes (9th & 10th version) corresponding to each grouping.
For the validation analysis, time-at-risk was from 1 April 2006 or the date of an individual’s
first attendance at drug treatment services if after 1 April 2006, until the earlier of date of death
or end-of-study, 31 March 2010. Time since most recent hospitalization was categorized as:
during hospitalization, within 28 days, 29–90 days, 91 days–1 year,>1 year after discharge
from most recent hospital-stay versus ‘never admitted’ (reference category). To be conservative,
deaths which occurred on the end-date of a hospitalization were counted as hospitalized
deaths. As in Merrall et al [14], hazard ratios from Cox proportional hazards analysis [20],
with adjustment for time-dependent covariates, are also reported.
For adequately-powered secondary analyses of behavioral risks (ever injecting drug users;
misuse of alcohol) and hospitalization covariates (length of stay; main discharge-diagnosis), we
considered the 1996–2010 SDMD cohort in its entirety so that at least 30 DRDs in the 28 days
after hospital-discharge might be available for analysis per discharge-diagnosis. Time-at-risk in
secondary analyses was from the date of an individual’s first attendance at drug treatment ser-
vices after 1 April 1996 until the earlier of date of death or end-of-study, 31 March 2010.
All statistical analyses were conducted using R version 2.15.0 [21].
Results
Characteristics of study population
Table 2 presents the characteristics of the study cohort, firstly for the SDMD clients first
observed during the era originally studied, April 1996 to March 2006, and secondly for those
first observed during April 2006 to March 2010. In the later era, an additional 23,734 individu-
als were newly registered in the SDMD cohort, with 14,474 subsequent hospital-stays and 168
Drugs-Related Death Soon after Hospital-Discharge
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DRDs during 50,453 person-years of follow-up. At their first registration in the 2006–2010 era,
68% were under 35 years of age (16,057) compared with 83% of those registered in the earlier
era; 36% (8,605) had a recorded history of injection drug use (past or present) compared with
49% of those in 1996–2006.
Table 3 presents descriptive statistics by follow-up era, with the 98,388 individuals contrib-
uting 334,421 person-years in the second follow-up era, 2006–2010, when there were 51,504
SDMD registrations, 78,658 hospital stays (based on 83,084 hospital-episodes and 11,818 psy-
chiatric-episodes) and 2,544 deaths (including 1,114 DRDs). Across eras, DRDs account for
about half of all deaths: 1409/2585 (55%) in 1996–2006 but 1114/2544 (44%) in 2006–2010.
Non-drug-related suicide accounted for 11% (284) of deaths in the first era, but for only 6%
(165) in the second. Conversely, diseases of the digestive system accounted for 6% (165) of
deaths in the first era, but for 13% (341) in the second.
The overall DRD-rate was 3.8 DRDs (95% CI: 3.6, 4.0) per 1,000 person-years in 1996–2006
but reduced to 3.3 DRDs (95% CI: 3.1, 3.5) per 1,000 person-years in 2006–2010.
Validation analysis: drugs-related deaths by time since hospitalization. Table 4 summa-
rizes DRD-rates by time since hospitalization in 1996–2006 and in the validation era of 2006–
2010. In both eras, DRD-risk was highest during hospitalization but hospitalized DRD-rate
decreased significantly from 74 DRDs per 1,000 person-years (95% CI: 61, 88) in 1996–2006 to
50 (95% CI: 39, 63) in 2006–2010. After discharge from a hospital-stay, DRD-rates per 1,000
person-years were consistent between eras: 24.6 and 22.5 within 28 days; 12.0 and 12.0 during
29–90 days; 8.3 and 8.6 for the remainder of the first year.
For each follow-up era Table 5 presents Cox Hazard Ratios by time since most recent hospi-
talization after adjustment for other DRD risk factors. In particular, note the influence of
reported misuse of alcohol in addition to having ever injected.
Consistently between 1996–2006 and 2006–2010 the hazard ratio is increased for reported
misuse of alcohol (1.48 and 1.45) and for hepatitis C virus diagnosis (1.31 and 1.28); but
reduced for females (0.54 and 0.58), and never-injectors (0.56 and 0.64). Relative to having
never been admitted, adjusted hazard ratios by recency of hospital-stay were: 11.8 and 15.1
within 28 days; 5.7 and 8.0 during 29–90 days; and 4.2 and 5.9 for the remainder of the first
year.
Behavioral risk-factors versus duration of hospital-stay or main discharge-diagnosis.
For the entire follow-up period of 1996–2010, Table 6 shows the DRD-rates by time since most
Table 2. Descriptive Statistics for characteristics at First SDMDRegistration by Registration Era, SDMDCohort, Scotland, 1996–2010.
Registration era: Apr 1996–Mar 2006 Apr 2006–Mar 2010
New SDMD clients (i.e. number of first registrations) 74,654 23,734
Male 51,856 69.5% 16,931 71.3%
Female 22,798 30.5% 6,803 28.7%
< 25 years 31,326 42.0% 7,408 31.2%
25–34 years 30,861 41.3% 8,649 36.4%
> 35 years 12,467 16.7% 7,677 32.3%
Injected in past month 24,402 32.7% 4,536 19.1%
Injected, but not in past month 12,485 16.7% 4,069 17.1%
Never injected 33,533 44.9% 13,776 58.0%
Unknown 4,234 5.7% 1,353 5.7%
Abbreviations: SDMD, Scottish Drugs Misuse Database
doi:10.1371/journal.pone.0141073.t002
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recent hospital-discharge, according to SDMD clients’ time-dependent ever injecting drug user
status and Table 7 shows the DRD-rates by reported alcohol misuse.
The DRD-rate during hospitalization is nearly three times higher for ever versus never
injecting drug users (88 versus 31 per 1,000 person-years). Moreover, within 28 days of hospi-
tal-discharge ever injecting drug users experienced a DRD-rate of 32 per 1,000 person-years
(95% CI: 27.7, 36.2) compared with 13 per 1,000 person-years (95% CI: 10.0, 16.4) for drug
treatment clients who had never injected. Reported misuse of alcohol, although associated with
Table 3. Descriptive Statistics for outcomes by Follow-up Era, SDMDCohort, Scotland, 1996–2010.
Follow-up era: Apr 1996–Mar 2006 Apr 2006–Mar 2010




Hepatitis C virus diagnosis 8,954 3,521
Total Deaths 2585 2544
Drugs-related deaths 1,409 54.5% 1,114 43.8%
Non-DRD suicidea 284 11.0% 165 6.5%
Diseases of the digestive system 165 6.4% 341 13.4%
Diseases of the circulatory system 125 4.8% 193 7.6%
Homicide 102 3.9% 60 2.4%
Accidental 93 3.6% 82 3.2%
Infectious and parasitic diseases 91 3.5% 65 2.6%
Cancer 69 2.7% 130 5.1%
Diseases of the respiratory system 64 2.5% 103 4.0%
Mental and behavioral disorders 60 2.3% 77 3.0%
Endocrine, nutritional and metabolic diseases 22 0.9% 25 1.0%
Diseases of the nervous system 16 0.6% 21 0.8%
Total hospital-stays 94,449 78,658 (14,474)b
Person-years follow-up 371,117 334,421 (50,453)b
Abbreviations: DRD, drugs-related death; SDMD, Scottish Drugs Misuse Database
a Excluding DRD suicides which are included in the DRD total,
b Restricted to individuals with first SDMD registration in 2006–2010 as in Table 1(a)
doi:10.1371/journal.pone.0141073.t003
Table 4. Drugs-related Death Rates by Follow-up Era and Time Since Hospital-discharge: Unadjusted, SDMDCohort, Scotland, 1996–2010.
By follow-up era: Apr 1996–Mar 2006 Apr 2006–Mar 2010
DRD Pys Rate (95% CI) DRD Pys Rate (95% CI)
Time since hospital-discharge
Never Admitted 458 257,643 1.8 (1.6, 2.0) 253 209,031 1.2 (1.1, 1.4)
Hospitalized 125 1,697 73.6 (61.3, 87.8) 75 1,497 50.1 (39.4, 62.8)
Within 28 days 165 6,714 24.6 (21.0, 28.6) 125 5,556 22.5 (18.7, 26.8)
29–90 days 131 10,918 12.0 (10.0, 14.2) 107 8,903 12.0 (9.9, 14.5)
91 days– 1-year 271 32,698 8.3 (7.3, 9.3) 235 27,306 8.6 (7.5, 9.8)
1+ years 259 61,446 4.2 (3.7, 4.8) 319 82,128 3.9 (3.5, 4.3)
Abbreviations: DRD, drugs-related death; SDMD, Scottish Drugs Misuse Database; Pys, Person-years; CI, Confidence Interval
doi:10.1371/journal.pone.0141073.t004
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Table 5. Drugs-related Death Rates by Follow-up Era and Time Since Hospital-discharge: Adjusted Using Cox Proportional Hazards Regression
With Calendar Time as the Underlying Time-scale, SDMDCohort, Scotland, 1996–2010.
Follow-up era Apr 1996–Mar 2006 Apr 2006–Mar 2010
Hazard ratio (95% CI) Hazard ratio (95% CI)
Age
< = 34 years (referent)
35+ years 1.16 (1.03, 1.31) 1.12 (1.00, 1.27)
Sex
Female 0.54 (0.47, 0.62) 0.58 (0.50, 0.68)
Male (referent)
Injector status
Inject in past month 1.25 (1.10, 1.42) 1.26 (1.09, 1.45)
Ever injected (referent)
Never injected 0.56 (0.48, 0.66) 0.64 (0.54, 0.76)
Unknown 0.62 (0.44, 0.87) 0.61 (0.42, 0.88)
Time since last SDMD registration
<12 weeks 1.34 (1.12, 1.60) 1.64 (1.29, 2.10)
3–12 months 1.09 (0.94, 1.26) 1.24 (1.02, 1.51)
1–2 years (referent)
2–5 years 0.80 (0.69, 0.92) 0.89 (0.75, 1.06)
5+ years 0.44 (0.34, 0.57) 0.61 (0.50, 0.74)
Misuse sedatives
Yes 1.08 (0.97, 1.21) 1.28 (1.13, 1.46)
No (referent)
Misuse stimulants
Yes 0.97 (0.83, 1.13) 1.04 (0.89, 1.22)
No (referent)
Misuse cannabis/tobacco
Yes 0.87 (0.76, 0.98) 0.80 (0.69, 0.93)
No (referent)
Misuse alcohol
Yes 1.48 (1.26, 1.73) 1.45 (1.26, 1.67)
No (baseline)
HCV diagnosis
Yes 1.31 (1.15, 1.50) 1.28 (1.10, 1.48)
No (referent)
Time since last hospitalised
Hospitalised 35.47 (29.01, 43.35) 32.92 (25.33, 42.79)
within 28 days 11.83 (9.87, 14.18) 15.09 (12.12, 18.80)
29–90 days 5.73 (4.71, 6.98) 8.01 (6.36, 10.08)
91 days– 1 year 4.15 (3.56, 4.84) 5.90 (4.91, 7.08)
1+ years 2.44 (2.09, 2.86) 2.88 (2.43, 3.41)
Never admitted (referent)
Abbreviations: SDMD, Scottish Drugs Misuse Database; CI, Confidence Interval
doi:10.1371/journal.pone.0141073.t005
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as high a DRD-rate in the 28 days after hospital-discharge, was a less prevalent risk-factor and
did not differentiate DRD-rate during hospitalization.
Table 8 shows DRD-rates within 28 days (and 90 days) after hospital-discharge by each of
the following: ever injecting drug use and reported alcohol misuse (from Tables 6 and 7); dura-
tion of hospital-stay and main discharge-diagnosis. There is no evident difference in DRD-rate
according to duration of hospital stay (0–1 days versus 2+ days). However, we observe some
variation in the DRD-rate by discharge-diagnosis.
Among discharge-diagnoses, only two—drug-related morbidity (for poisoning by drugs,
medicaments and biological substances plus mental and behavioral disorders due to psychoac-
tive substance misuse) and mental and behavioral disorders excluding those due to psychoac-
tive substances—were associated with at least 30 DRDs within 28 days after discharge and also
had high DRD-rates per 1,000 person-years, 39 (95% CI: 30.1, 47.8) and 36 (95% CI: 27.0, 46.9)
respectively, as did diseases of the respiratory system, 37 (95% CI: 23.1, 55.9). Together, these
top three discharge-diagnoses accounted for only 52% (150/290) of the SDMD cohort’s DRDs
within 28 days after hospital-discharge.
By contrast, ever injecting drug users accounted for 77% (222/290) of DRDs in the 28 days
after hospital-discharge. The SDMD clients who reported misuse of alcohol had a correspond-
ingly high DRD-rate soon after hospital-discharge but accounted for only 31% (89/290) of all
SDMD clients’DRDs in the 28 days after hospital-discharge.
Ever injecting drug users’ short-term risk can be summarized as one DRD (95% CI: 0.85,
1.11) in the 28 days after hospital-discharge per 400 discharged SDMD clients who had ever
injected.
Table 6. Drugs-related Death Rates Soon After Hospital-discharge for Ever-IDU Behavioral Risk-factor, SDMDCohort, Scotland, 1996–2010.
Injector-status: Ever Injected Never known to have injected
DRD PYs Rate (95% CI) DRD PYs Rate (95% CI)
Never Admitted 512 250,555 2.0 (1.9, 2.2) 199 216,119 0.9 (0.8, 1.1)
Hospitalised 156 1,771 88.1 (74.8,103.0) 44 1,423 30.9 (22.5, 41.5)
Within 28 days 222 6,998 31.7 (27.7, 36.2) 68 5,271 12.9 (10.0, 16.4)
29–90 days 171 11,506 14.9 (12.7, 17.3) 67 8,316 8.1 (6.2, 10.2)
91 days– 1 year 380 35,820 10.6 (9.6, 11.7) 126 24,183 5.2 (4.3, 6.2)
1+ years 458 92,362 5.0 (4.5, 5.4) 120 51,212 2.3 (1.9, 2.8)
doi:10.1371/journal.pone.0141073.t006
Table 7. Drugs-related Death Rates Soon After Hospital-discharge for ReportedMisuse of Alcohol Behavioral Risk-factor, SDMDCohort, Scotland,
1996–2010.
Alcohol misuse: Yes No
DRD PYs Rate (95% CI) DRD PYs Rate (95% CI)
Never Admitted 132 60,437 2.2 (1.8, 2.6) 579 406,237 1.4 (1.3, 1.5)
Hospitalised 41 653 62.8 (45.1, 85.2) 159 2,542 62.6 (53.2, 73.1)
Within 28 days 89 2,655 33.5 (26.9, 41.3) 201 9,615 20.9 (18.1, 24.0)
29–90 days 47 4,093 11.5 (8.4, 15.3) 191 15,728 12.1 (10.5, 14.0)
91 days– 1 year 113 11,324 10.0 (8.2, 12.0) 393 48,680 8.1 (7.3, 8.9)
1+ years 105 20,493 5.1 (4.2, 6.2) 473 123,082 3.8 (3.5, 4.2)
Abbreviations: DRD, drugs-related death; SDMD, Scottish Drugs Misuse Database; Pys, Person-years; CI, Confidence Interval; IDU, Injecting Drug User
doi:10.1371/journal.pone.0141073.t007
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Discussion
Our key confirmatory finding is that DRD-rates by time since most recent hospitalization
remained significantly higher in the 28 days after hospital-discharge than at subsequent times
post-discharge (with and without covariate adjustment). The SDMD cohort’s DRD-rate while
hospitalized had decreased in 2006–2010, but absolute DRD-risks soon after hospital-discharge
remained similar across both periods.
New SDMD registrations in the validation period of 2006–2010 were different from those in
the earlier registration period in important respects: a higher proportion of 2006–2010 regis-
tered clients were 35 years of age or older at registration than among clients whose first SDMD
registration was in 1996–2006, and a higher proportion reported never having injected. This
suggests that Scottish drug users are not only ageing but that newer clients are less likely to
have been initiated into injecting.
The study disputed our hypothesis that individuals who are hospitalized for a longer time
(at least overnight) may be at greater DRD-risk post-discharge due to loss of tolerance. How-
ever, the duration of hospital-stay was a highly skewed variable; with a few individuals
experiencing very long (several months) periods. There was insufficient statistical power to
Table 8. Drugs-related Death Rates Soon After Hospital-dischargeWithin 28 and 90 Days After Hospital-discharge by Duration of Hospital-stay
and Main Discharge-diagnosis Versus Ever-IDU and Reported Misuse of Alcohol, SDMD Cohort, Scotland, 1996–2010.
Soon after hospital-discharge Within 28 days after discharge Within 90 days after discharge
DRD Pys Rate (95% CI) DRD Pys Rate (95% CI)
Rate for SDMD cohort, 1996–2010 290 12,270 23.6 (21.0, 26.5) 528 32,091 16.5 (15.1, 17.9)
By injector status
Ever-IDU 222 6,998 31.7 (27.7, 36.2) 393 18,504 21.2 (19.1, 23.3)
Never or not known to have injected 68 5,271 12.9 (10.0, 16.4) 135 13,587 9.9 (8.3, 11.6)
By reported misuse of alcohol
Yes 89 2,655 33.5 (26.9, 41.3) 136 6,748 20.2 (16.8, 23.5)
No 201 9,615 20.9 (18.1, 24.0) 392 25,343 15.5 (13.9, 17.0)
By duration of hospital-stay
0–1 day 160 6,781 23.6 (20.1, 27.5) 277 17,957 15.4 (13.7, 17.4)
2+ days 130 5,488 23.7 (19.8, 28.1) 251 14,134 17.8 (15.6, 20.1)
By main discharge-diagnosis
Other diagnosesa 93 5,836 15.9 (12.9, 19.5) 205 16,607 13.1 (11.4, 15.1)
Drugs-related morbidityb 74 1,899 39.0 (30.1, 47.8) 137 4,996 27.4 (22.8, 32.0)
Mental and behavioral disordersc 54 1,503 35.9 (27.0, 46.9) 80 3,782 21.2 (16.8, 26.3)
Diseases of the respiratory system 22 596 36.9 (23.1, 55.9) 34 1,559 21.8 (15.1, 30.5)
Cancer 3 116 25.8 (5.3, 75.4) 3 199 15.1 (3.1, 44.1)
Infectious and parasitic diseases 6 260 23.1 (8.5, 50.2) 7 688 10.2 (4.1, 21.0)
Diseases of the circulatory system 12 576 20.8 (10.8, 36.4) 21 1,502 14.0 (8.7, 21.4)
Endocrine, nutritional and metabolic diseases 3 149 20.1 (4.2, 58.9) 5 344 14.5 (4.7, 33.9)
Diseases of the digestive system 22 1,165 18.9 (11.8, 28.6) 32 1,974 10.8 (7.4, 15.2)
Diseases of the nervous system 1 170 5.9 (0.1, 32.8) 4 440 9.1 (2.5, 23.3)
Abbreviations: DRD, drugs-related death; SDMD, Scottish Drugs Misuse Database; Pys, Person-years; CI, Confidence Interval; IDU, Injecting Drug User
a All diagnoses not included in specified groups
b Diagnoses related to drug misuse, (a) Poisonings by drugs, medicaments & biological substances and (b) Mental & behavioral disorders due to
psychoactive substance
c All mental and behavioral disorders, excluding those due to psychoactive substances
doi:10.1371/journal.pone.0141073.t008
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properly investigate the effect of short versus long stay lengths. A further subdivision of dura-
tion of hospital-stay as 0–1 day, 2–6 days and 7+ days (results not shown) also showed no dif-
ference between stays of less than versus greater than one week.
The influence of main discharge-diagnosis on subsequent DRD-risk was also analyzed by
grouping the codes into pre-specified categories as used previously by Merrall et al. [4]. We
needed to consider the entire SDMD cohort in order to have sufficient power per discharge-
category and, even so, only two main discharge-diagnoses exceeded 30 DRDs within 28 days
after hospital-discharge. These two discharge-categories were drug-related morbidity and men-
tal and behavioral disorders excluding psychoactive substance misuse. Even together with dis-
eases of the respiratory system, these top three DRD-risk discharge-categories accounted for
only 52% (150/290) DRDs in the 28 days after hospital-discharge.
By contrast, behavioral risk-factors were far more discriminatory with ever injecting drug
use accounting for the vast majority (77%: 222/290) of DRDs in the 28 days after discharge.
This finding gives added focus to Scotland’s public health policy to make take-home naloxone
(opiate antagonist) readily available, as well as training in its administration, not only in pri-
sons and at drug treatment agencies but also at discharge from hospital, see [22] and [23].
Moreover, our new results suggest how hospital doctors can best target their harm reduction
response [24]–not ineffectually according to patients’ length of hospital-stay, nor too narrowly
by concentrating on a few main discharge-diagnoses, but highly efficiently by focusing on
those who have ever injected. For ever injecting drug users, we note that one DRD in the 28
days after hospital-discharge per 400 discharges is about half their estimated DRD-risk in the
28 days after prison-release [25].
For the SDMD cohort of over 98,000 drug treatment clients in Scotland, we have confirmed
that a high DRD risk soon after hospital-discharge applies in 2006–2010 as it did in 1996–2006
[14]. Length of hospital-stay had no effect on DRD-rate, discharge-diagnosis had an effect (as
did reported misuse of alcohol) but neither was as discriminatory as the behavioral risk-factor
of having ever injected.
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